Paul Goode - 25 Mar 2025 Form 4 Insider Report for Glucotrack, Inc. (GCTK)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: GCTK
Reported as of: 25 Mar 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Oct 2025, 19:26:08 UTC
Prior SEC filing: 03 Jul 2024
Source filing: View source filing
Reporting owner signature: /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact

Key filing fact

Paul Goode filed Form 4 for Glucotrack, Inc. (GCTK) on 07 Oct 2025.

Key facts

This page summarizes Paul Goode's Form 4 filing for Glucotrack, Inc. (GCTK).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 07 Oct 2025, 19:26.

Change

Previous filing in this sequence was filed on 03 Jul 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001622251 Primary reporting owner

Goode Paul

Relationship: Chief Executive Officer, Director
Address: C/O GLUCOTRACK, INC., 301 RTE. 17 NORTH, SUITE 800, RUTHERFORD
Signature: /s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact
Signature date: 07 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GCTK transaction

Common Stock, par value $0.001 per share

Other

Transaction value
Shares: +42
Change %: +14%
Price
Shares after: 339
Date: 25 Mar 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On October 7, 2022, the reporting person entered into an into Intellectual Property Purchase Agreement (the "IP Purchase Agreement") with Glucotrack, Inc. (the "Issuer"), pursuant to which the reporting person is entitled to certain specified milestone payments, payable in common stock, par value $0.001 per share, of the Issuer (the "Common Stock"), as set forth in the IP Purchase Agreement. Upon the achievement of the third milestone contemplated by the IP Purchase Agreement, the reporting person was issued 42 shares of Common Stock, pursuant to the terms of the IP Purchase Agreement.

SEC remarks

On May 17, 2024, a 1-for-5 reverse stock split of the Issuer's Common Stock was implemented (the "2024 Reverse Split"). On February 25, 2025, a 1-for-20 reverse stock split of the Common Stock was implemented (the "February 2025 Reverse Split"), and on June 13, 2025, a 1-for-60 reverse stock split of the Common Stock was implemented (the "June 2025 Reverse Stock Split", and together with the 2024 Reverse Split and the February 2025 Reverse Stock Split, the "Reverse Stock Splits"). All figures presented in this Form 4 reflect the Reverse Stock Splits.